NDLI: Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.

Please wait, while we are loading the content...

Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.

Content Provider	Semantic Scholar
Author	Bonderman, Diana Nowotny, Regina Skoro-Sajer, Nika Jakowitsch, Johannes Adlbrecht, Christopher Klepetko, Walter Lang, Irene M.
Copyright Year	2005
Abstract	BACKGROUND Bosentan, an oral endothelin (ET)-A/ET-B receptor antagonist, is effective in the treatment of pulmonary arterial hypertension. OBJECTIVE To investigate the safety and efficacy of bosentan therapy in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). DESIGN Case series. SETTING Pulmonary Hypertension Unit of the Medical University of Vienna, Austria. PATIENTS Sixteen patients (9 women and 7 men; mean age +/- SD, 70 +/- 13 years). INTERVENTION Off-label bosentan treatment over 6 months. MEASUREMENTS Changes from baseline in liver enzymes, New York Heart Association (NYHA) functional class, 6-min walking distance (6-MWD), and serum amino-terminal pro-brain natriuretic peptide (proBNP). RESULTS After 6 months, NYHA functional class improved by one class in 11 patients. Mean 6-MWDs increased from 299 +/- 131 m at baseline to 391 +/- 110 m at 6 months (p = 0.01). In parallel, proBNP decreased from 3,365 +/- 2,923 to 1,755 +/- 1,812 pg/mL (p = 0.01). Neither aspartate aminotransferase (25 +/- 2 U/L vs 25 +/- 2 U/L, p = 0.25) nor alanine aminotransferase (23 +/- 12 U/L vs 24 +/- 9 U/L, p = 0.57) changed significantly. Limitations of the study were uncontrolled design and small sample size. CONCLUSIONS Our study suggests a beneficial effect of the oral dual ET receptor antagonist bosentan in patients with inoperable CTEPH, urging the need for a randomized, placebo-controlled trial.
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://journal.publications.chestnet.org/pdfaccess.ashx?url=/data/journals/chest/22032/2599.pdf
PubMed reference number	16236930v1
Volume Number	128
Issue Number	4
Journal	Chest
Language	English
Access Restriction	Open
Subject Keyword	Alanine Aspartate Transaminase Aspartic Acid Chronic thromboembolic pulmonary hypertension Dual Endothelin Heart valve disease Hypertensive disease Lichen Sclerosus et Atrophicus Nesiritide Patients Physiological Sexual Disorders Somnambulism Transaminases bosentan natriuretic
Content Type	Text
Resource Type	Article

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in